Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries (INSIGHT)

Avinger

Status

Completed

Conditions

Peripheral Arterial Disease

Treatments

Device: Atherectomy Catheter

Study type

Interventional

Funder types

Industry

Identifiers

NCT03192696

P0942

Details and patient eligibility

About

A prospective, non-randomized, international, multi-center study to evaluate the safety and effectiveness of the Pantheris OCT-Imaging System to perform atherectomy in In-Stent Restenotic (ISR) lesions in lower extremity arteries.

Full description

This is a prospective, global, single-arm, multi-center study to evaluate the safety and effectiveness of the Pantheris OCT-Imaging System to perform atherectomy of in-stent restenotic (ISR) lesions in lower extremity arteries.

The trial will enroll up to 140 subjects diagnosed with peripheral arterial disease of the lower extremities that have previously been treated with stenting at up to 20 sites. The primary disease must be located in reference vessel diameter of >3.0mm and ≤7.0mm. Trial success is focused on safety, including rates of major adverse events through 30 days as adjudicated by a Clinical Events Committee, and effectiveness, which will be evaluated using technical success defined as the percent of target lesions that have residual diameter stenosis <50% post-treatment with the Pantheris device alone as assessed by Angiographic Core Lab.

Enrollment

127 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject is >18 years old;
Subject is willing and able to give informed consent;
Subject has Rutherford Classification of I-V;
Subject presenting with a single Class I, II or III ISR lesion as per Tosaka's Classification criteria in the lower leg extremities;
Target lesion must be >70% stenosed and within a stented segment by angiographic visual estimation;
Reference vessel lumen acceptable for treatment with Pantheris catheter size as per visual angiographic estimation;
Target lesions must be within the stented segment and no more than 3 cm past the proximal or distal portions of the stent;
Target lesion is ≤30 cm in length;
Intraluminal crossing of totally occluded lesions prior to atherectomy;
At least one patent tibial run-off vessel at baseline; and
Subject is capable of meeting requirements and be present at the follow-up clinic visits at 30 days, 6 months and 12 months.

Exclusion criteria

Subject is pregnant or breast feeding;
Rutherford Class 0 or VI;
Severe calcification of the target lesion;
Acute ischemia and/or acute thrombosis of the target lesion segment;
Target lesion with a covered stent;
Target lesion in the iliac artery;
Target lesion stenosis <70%;
Target lesion >30 cm in length;
Subjects with totally occluded stented segments that are not successfully crossed intraluminally prior to atherectomy treatment;
Grade 4 or 5 stent fracture affecting target stent, or where evidence of stent protrusion into the lumen is noted on angiography in two orthogonal views;
Subjects on chronic hemodialysis or creatinine level >2.5 mg/dL;
CVA or stroke within 60 days prior to the index procedure;
Endovascular or surgical procedure performed on the index limb less than or equal to 30 days prior to the index procedure;
Planned endovascular or surgical procedure 30 days after the index procedure;
Lesion in the contralateral limb requiring intervention during the index
procedure or within 30 days of the index procedure;
Known allergy to contrast agents or medications used to perform endovascular
intervention that cannot be adequately pre-treated;
Subjects in whom anti-platelet, aspirin, anticoagulant, or thrombolytic therapy is contraindicated;
Any thrombolytic therapy within 2 weeks of the index procedure;
Any clinical and/or angiographic complication attributed to the use of another device prior to the insertion of the study device into the subject during the index procedure;
Subjects or their legal guardians who have not or will not sign the Informed Consent;
Subjects who are unwilling or unable to comply with the follow-up study
requirements; or
Participation in any study of an investigational device, medication, biologic or other agent within 30 days prior to enrollment that is either a cardiovascular study or could, in the judgment of the investigator, affect the results of the study.